Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase.

Fragment-based drug design was successfully applied to maternal embryonic leucine zipper kinase (MELK). A low affinity (160 μM) fragment hit was identified, which bound to the hinge region with an atypical binding mode, and this was optimized using structure-based design into a low-nanomolar and cell-penetrant inhibitor, with a good selectivity profile, suitable for use as a chemical probe for elucidation of MELK biology.

[1]  M. Bollen,et al.  Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells. , 2013, The Journal of Biological Chemistry.

[2]  D. Ito,et al.  Development of selective MELK kinase inhibitors for breast cancer treatment , 2016 .

[3]  G. Canevari,et al.  Structural insight into maternal embryonic leucine zipper kinase (MELK) conformation and inhibition toward structure-based drug design. , 2013, Biochemistry.

[4]  Zhi-Xin Wang,et al.  Structural Basis for the Regulation of Maternal Embryonic Leucine Zipper Kinase , 2013, PloS one.

[5]  Leonard A. Smith,et al.  The C Terminus of the Catalytic Domain of Type A Botulinum Neurotoxin May Facilitate Product Release from the Active Site* , 2013, The Journal of Biological Chemistry.

[6]  Kaushal Joshi,et al.  Tumor‐Specific Activation of the C‐JUN/MELK Pathway Regulates Glioma Stem Cell Growth in a p53‐Dependent Manner , 2013, Stem cells.

[7]  Matthias Rarey,et al.  Torsion angle preferences in druglike chemical space: a comprehensive guide. , 2013, Journal of medicinal chemistry.

[8]  Kaushal Joshi,et al.  MELK-Dependent FOXM1 Phosphorylation is Essential for Proliferation of Glioma Stem Cells , 2013, Stem cells.

[9]  Yusuke Nakamura,et al.  Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer , 2012, Oncotarget.

[10]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[11]  H. Klocker,et al.  The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer , 2012, Journal of Molecular Medicine.

[12]  Chenglong Li,et al.  Novel Inhibitor Discovery through Virtual Screening against Multiple Protein Conformations Generated via Ligand-Directed Modeling: A Maternal Embryonic Leucine Zipper Kinase Example , 2012, J. Chem. Inf. Model..

[13]  J. Hassell,et al.  Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. , 2010, Cancer research.

[14]  J. Ku,et al.  Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. , 2010, Carcinogenesis.

[15]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[16]  J. Zierath,et al.  Hunting for the SNARK in metabolic disease. , 2009, American journal of physiology. Endocrinology and metabolism.

[17]  M. Chen,et al.  Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase , 2009, Clinical and translational science.

[18]  Carlos Caldas,et al.  Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer , 2009, Breast Cancer Research.

[19]  D. Ross,et al.  TLE3 as a candidate biomarker of response to taxane therapy , 2009, Breast Cancer Research.

[20]  Paul S Mischel,et al.  Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells , 2008, Journal of neuroscience research.

[21]  Paul Bamborough,et al.  Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode. , 2008, Bioorganic & medicinal chemistry letters.

[22]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[23]  R. Alani,et al.  Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of Melanoma Progression , 2007, PloS one.

[24]  Marcel L Verdonk,et al.  Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.

[25]  Sungjoon Kim,et al.  Ba/F3 cells and their use in kinase drug discovery , 2007, Current opinion in oncology.

[26]  Yusuke Nakamura,et al.  Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family , 2007, Breast Cancer Research.

[27]  M. Bollen,et al.  Substrate Specificity and Activity Regulation of Protein Kinase MELK* , 2005, Journal of Biological Chemistry.

[28]  David P. Davis,et al.  Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. , 2005, Cancer research.

[29]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[30]  Jérôme Boudeau,et al.  LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1 , 2004, The EMBO journal.

[31]  W. F. Hoffman,et al.  Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. , 2002, Bioorganic & medicinal chemistry letters.

[32]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[33]  H. Ha,et al.  Cloning and expression of a cDNA encoding a novel protein serine/threonine kinase predominantly expressed in hematopoietic cells. , 1997, Gene.